Prognostic factors for overall survival in patients with metastatic castration-resistant prostate cancer treated with radium-223: a meta-analysis of real-world evidence
{{output}}
Background: Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with limited treatment options. Radium-223 (Ra-223) improves survival in bone-predominant mCRPC, but real-world outcomes vary widely. Th... ...
